Tuesday, November 24, 2020

Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

The Charade of New Drug Approvals for Schizophrenia

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Withdrawal from Antipsychotics

A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.

The Case Against Antipsychotics

This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Danish Study Finds Better 10-year Outcomes in Patients Off Antipsychotics

Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.

Anticholinergic Psychiatric Drugs Linked to a 50% Increase in Dementia

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
digital antipsychotic

The Rise of the Digital Asylum

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

Do Antipsychotics Protect Against Early Death? A Review of the Evidence

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

New Research Suggests Brain Abnormalities in ‘Schizophrenia’ May Result From Antipsychotics

Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.

A Tale of Two Studies

With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?

Antipsychotic Medications Are Causing Obsessive Compulsive Disorders

Common second-generation antipsychotic medications are causing symptoms of obsessive-compulsive disorder to emerge in many people who previously only had schizophrenia symptoms, according to a...

Largest Survey of Antipsychotic Experiences Reveals Negative Results

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Safety Analysis Weighs Harms and Benefits of Antipsychotic Drugs

The researchers find that the drug effects for reducing psychosis are small and that treatment failure and severe side effects are common.

Antipsychotics Linked to Cognitive & Memory Impairments

Finnish reseachers report in Schizophrenia Research that antipsychotic use is associated with cognitive and memory impairments. The University of Oulu team studied forty people...

Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

Antipsychotics Associated with Severe COVID-19 and Fatal Outcomes

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

Study Finds Improved Functioning for ‘Schizophrenia’ Without Antipsychotics

Long-term treatment with antipsychotic drugs is currently considered the standard treatment for patients diagnosed with ‘schizophrenia.’ A new study challenges this practice, however. The...

Study Suggests Long-Term Antipsychotic Use May Result in Poorer Cognitive Functioning

Association found between long-term antipsychotic use and poorer performance on cognitive tasks in adults diagnosed with ‘schizophrenia.’

Researchers Warn of “Brain Atrophy” in Children Prescribed Antipsychotics

Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.

Scientists Clarify Risks of Augmenting with Antipsychotic Medications for Depression

The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.

A Guide to Minimal Use of Neuroleptics

This guide, by psychiatrists Volkmar Aderhold and Peter Stastny, provides a comprehensive review of antipsychotics and an evidence-based rationale for avoiding their use in first-episode psychosis, and for minimizing their long-term use.

Patients With Schizophrenia Show Better Work Functioning Off Antipsychotics

20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.

Follow Us

19,639FansLike
11,994FollowersFollow
4,730SubscribersSubscribe